Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SOLV · NYSE · Health Care Technology
Solventum (SOLV) · oqro.io/stocks/SOLV · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$84.50−1.30 (−1.52%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Solventum was filed in the last 90 days. The latest on record was on Mar 11, 2026.
Since 2025, Solventum insiders reported 1 open-market purchase and 1 sale on Forms 4 and 5, with purchases in 1 different year, most recently 2026.
No open-market sale by an insider of Solventum (SOLV) was filed with the SEC in the last 90 days.
Yes. Members of Congress disclosed 3 trades in Solventum (SOLV) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Sen. Tommy Tuberville, Sen. Alan Armstrong, Rep. J. French Hill (AR02).
Solventum's next results are expected on Feb 24, 2027, before the market opens. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+6.3% (+$4.99) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $79.51 on Nov 20, 2025 to $84.50 on Nov 20, 2026 (+6.3%). Disclosed in this range: 1 insider trade, 0 pre-arranged insider sales, 2 Congress trades, and 21 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Technology company based in Saint Paul, Minnesota.
Last 12 months
+6.3%
Market value
$14.3B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 5.05M shares sold short (3.0% of shares outstanding), +1.9% vs the previous count, 4.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$8.32B
+0.9% vs the year before
Net income, fiscal 2025
$1.56B
As reported in the annual filing
Shares outstanding
170M
As of Oct 31, 2026
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
17 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 13, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
17 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 7, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
27 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 6, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$1.95B
−7.0% vs the same quarter a year earlier
Free cash flow, last 12 months
$0
This quarter $97M, a year earlier −$21M
Net debt
$4.62B
Debt $5.07B, cash $451M, at Sep 30, 2026
Net income, last 12 months
$156M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue and earnings history, 4 fiscal yearsRevenue breakdown: where the money goesCompared with its peersEarnings dates and the stock's moves
On the public record for Solventum over the 12 months to Nov 21, 2026: 2 FDA records.
Insiders of Solventum reported 1 open-market purchase and 1 sale since 2025; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $100K1×1 trade | — |
| 2025 | — | $646M1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 19, 2025, SOLV is up 9.3% and the index fund is up 4.1%: 5 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SOLV moves
Beta 0.6 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Top officer leaving
“Zieselman is replacing Mary Wilcox in this role in connection with her previously announced retirement and will report directly to Wayde McMillan, the Company’s Chief Financial Officer.”
8-K on sec.govTop officer leaving
“The Severance Plan includes several changes compared to the Prior Plan, including, but not limited to: • The Severance Plan provides for 12 months of base salary plus prorated incentive compensation following an eligible termination for direct reports of the Chief Executive Officer, provided that currently serving executive officers who are eligible to receive 18 months of base salary remain eligi”
8-K on sec.govTop officer leaving
“On March 20, 2026, Mary Wilcox informed Solventum Corporation (the “Company”) of her intent to retire and resign from her position as Chief Accounting Officer of the Company following a search for and appointment of her successor.”
8-K on sec.govTop officer leaving
“Knight’s appointment, Chris Barry, Executive Vice President and Group President of MedSurg, will depart the Company effective December 31, 2025.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Independent Franchise Partners, LLP
13G · passive · Up from 7.44% · 15.4M shares · filed Jan 27, 2026
Vanguard Capital Management
13G · passive · Crossed 5% · 10.9M shares · filed Apr 30, 2026
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Attention
Things to keep in mind
People read Solventum's Wikipedia article about 66 times a day over the last week, fewer than the 89 on a usual day of the three months before.
May 16, 2026Busiest day: 170 views on May 19, 2026Nov 21, 2026
Views of the article Solventum, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
2 approvals or clearances and 0 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 24, 2027
before the market opens; the date can move until the company confirms it
Purchases after results
Not enough history
From Solventum's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Solventum's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 27, 2026. Read the filing
+3.9% on the year before ($4.64B). Operating income $810M, a 17% margin
+4.1% on the year before ($1.31B). Operating income $496M, a 36% margin
+4.2% on the year before ($1.29B). Operating income $346M, a 26% margin
−30% on the year before ($709M). Operating income $96M, a 19% margin
The segments reach the total once $302M of items outside them is counted: corporate items, and the removal of sales between segments so they are not counted twice, as the company reports them.
0.0% on the year before ($6.35B)
+3.7% on the year before ($1.91B)
+2.4% on the year before ($4.56B)
−1.0% on the year before ($3.69B)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
Solventum is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs. We constantly seek to enable the improvement of standards of care and move healthcare forward with innovation powered by insights, clinical intelligence, technology, and manufacturing expertise. Our 70+ year history of discovering and innovating advanced solutions has helped us solve our customers’ toughest challenges and become a trusted partner.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 27, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Feb 27, 2026, compared with the one filed Feb 28, 2025. Read the filing
Discussion of legal matters is incorporated by reference from Part II, Item 8, Note 12, "Commitments and Contingencies," to the consolidated financial statements, and should be considered an integral part of Part I, Item 3, "Legal Proceedings."
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 27, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Short sale volume: 50.2% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 55.3%. FINRA daily files, to Nov 20, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Off-exchange trading: 41.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (26.5% on ATS, 14.7% with other brokers), close to its 26-week average of 40.9%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: UBS ATS (12.7%), INTELLIGENT CROSS LLC (11.9%), SIGMA X2 (10.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.